Prognostic factors and outcomes of severe gastrointestinal GVHD after allogeneic hematopoietic cell transplantation

Bone Marrow Transplantation

Volumn 49, Issue 7, 2014, Pages 966-971

  Castilla Llorente, C ^a,c   Martin, P J ^a,b   McDonald, G B ^a,b   Storer, B E ^a,b   Appelbaum, F R ^a,b   Deeg, H J ^a,b   Mielcarek, M ^a,b   Shulman, H ^a,b   Storb, R ^a,b   Nash, R A ^a,b,d  

^a USA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c HOSPITAL MORALES MESEGUER   (Spain)

^d Rocky Mountain Blood and Marrow Transplant Program   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; CYTARABINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGE DISTRIBUTION; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER RECURRENCE; CAUSE OF DEATH; CHEMOPROPHYLAXIS; CHILD; CLOSTRIDIUM DIFFICILE INFECTION; DISEASE SEVERITY; DRUG MEGADOSE; DRUG RESPONSE; FEMALE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL GRAFT VERSUS HOST DISEASE; GASTROINTESTINAL HEMORRHAGE; GRAFT VERSUS HOST REACTION; HIGH RISK POPULATION; HUMAN; LIVER GRAFT VERSUS HOST DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; MYELOABLATIVE CONDITIONING; OUTCOME ASSESSMENT; PATIENT IDENTIFICATION; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; RISK FACTOR; SKIN GRAFT VERSUS HOST DISEASE; SURVIVAL RATE; SURVIVAL TIME; YOUNG ADULT; ADOLESCENT; ADVERSE EFFECTS; ALLOTRANSPLANTATION; GASTROINTESTINAL DISEASES; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INFANT; PRESCHOOL CHILD; PROCEDURES; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; FEMALE; GASTROINTESTINAL DISEASES; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; MALE; MIDDLE AGED; PROGNOSIS; RISK FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84903899040     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2014.69     Document Type: Article

References (39)

1. Leisenring WM, Martin PJ, Petersdorf EW, Regan AE, Aboulhosn N, Stern JM et al. An acute graft-versus-host disease activity index to predict survival after hematopoietic cell transplantation with myeloablative conditioning regimens. Blood 2006; 108: 749-755.
2. Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 2010; 363: 2091-2101.
3. Hockenbery DM, Cruickshank S, Rodell TC, Gooley T, Schuening F, Rowley S et al. A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease. Blood 2007; 109: 4557-4563.
4. Baehr PH, Levine DS, Bouvier ME, Hockenbery DM, Gooley TA, Stern JG et al. Oral beclomethasone dipropionate for treatment of human intestinal graft-versus-host disease. Transplantation 1995; 60: 1231-1238.
5. Wakui M, Okamoto S, Ishida A, Kobayashi H, Watanabe R, Yajima T et al. Prospective evaluation for upper gastrointestinal tract acute graft-versus-host disease after hematopoietic stem cell transplantation. Bone Marrow Transplant 1999; 23: 573-578.
6. Wu D, Hockenbery DM, Brentnall TA, Baehr PH, Ponec RJ, Kuver R et al. Persistent nausea and anorexia after marrow transplantation: a prospective study of 78 patients. Transplantation 1998; 66: 1319-1324.
7. Mielcarek M, Storer BE, Boeckh M, Carpenter PA, McDonald GB, Deeg HJ et al. Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes. Blood 2009; 113: 2888-2894.
8. Castilla C, Perez-Simon JA, Sanchez-Guijo FM, Diez-Campelo M, Ocio E, Perez-Persona E et al. Oral beclomethasone dipropionate for the treatment of gastrointestinal acute graft-versus-host disease (GVHD). Biol Blood Marrow Transplant 2006; 12: 936-941.
9. Schwartz JM, Wolford JL, Thornquist MD, Hockenbery DM, Murakami CS, Drennan F et al. Severe gastrointestinal bleeding after hematopoietic cell transplantation, 1987-1997: incidence, causes, and outcome. Am J Gastroenterol 2001; 96: 385-393.
10. Ross WA, Couriel D. Colonic graft-versus-host disease. Curr Opin Gastroenterol 2005; 21: 64-69.
11. Martin PJ, Schoch G, Fisher L, Byers V, Anasetti C, Appelbaum FR et al. A retrospective analysis of therapy for acute graft-versus-host disease: Initial treatment. Blood 1990; 76: 1464-1472.
12. Nash RA, Antin JH, Karanes C, Fay JW, Avalos BR, Yeager AM et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000; 96: 2062-2068.
13. Nash RA, Johnston L, Parker P, McCune JS, Storer B, Slattery JT et al. A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2005; 11: 495-505.
14. McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graftversus- tumor effects. Blood 2001; 97: 3390-3400.
15. Maris MB, Niederwieser D, Sandmaier BM, Storer B, Stuart M, Maloney D et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood 2003; 102: 2021-2030.
16. Ponec RJ, Hackman RC, McDonald GB. Endoscopic and histologic diagnosis of intestinal graft-versus-host disease after marrow transplantation. Gastrointest Endosc 1999; 49: 612-621.
17. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295-304.
18. Przepiorka D, Weisdorf D, Martin P, Klingemann H-G, Beatty P, Hows J et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825-828.
19. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18: 695-706.
20. MacMillan ML, Defor TE, Weisdorf DJ. What predicts high risk acute graft-versushost disease (GVHD) at onset?: identification of those at highest risk by a novel acute GVHD risk score. Br J Haematol 2012; 157: 732-741.
21. Robin M, Porcher R, de Castro R, Fisher G, de Latour RP, Ribaud P et al. Initial liver involvement in acute GVHD is predictive for nonrelapse mortality. Transplantation 2009; 88: 1131-1136.
22. McDonald, GB Sale, GE. The human gastrointestinal tract after allogeneic marrow transplantation in humans. In: Sale, GE Shulman, HM (eds) The Pathology of Bone Marrow Transplantation. Masson, Inc.: New York, 1984, 77-103.
23. Kreisel W, Dahlberg M, Bertz H, Harder J, Potthof K, Deibert P et al. Endoscopic diagnosis of acute intestinal GVHD following allogeneic hematopoietic SCT: a retrospective analysis in 175 patients. Bone Marrow Transplant 2012; 47: 430-438.
24. Ferrara JL, Harris AC, Greenson JK, Braun TM, Holler E, Teshima T et al. Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease. Blood 2011; 118: 6702-6708.
25. Harris AC, Ferrara JL, Braun TM, Holler E, Teshima T, Levine JE et al. Plasma biomarkers of lower gastrointestinal and liver acute GVHD. Blood 2012; 119: 2960-2963.
26. Melson J, Jakate S, Fung H, Arai S, Keshavarzian A. Crypt loss is a marker of clinical severity of acute gastrointestinal graft-versus-host disease. Am J Hematol 2007; 82: 881-886.
27. MacMillan ML, Weisdorf DJ, Wagner JE, Defor TE, Burns LJ, Ramsay NK et al. Response of 443 patients to steroids as primary therapy for acute graft-versushost disease: comparison of grading systems. Biol Blood Marrow Transplant 2002; 8: 387-394.
28. Pidala J, Anasetti C. Glucocorticoid-refractory acute graft-versus-host disease . Biol Blood Marrow Transplant 2010; 16: 1504-1518.
29. Jamani K, Russell JA, Daly A, Stewart D, Savoie L, Duggan P et al. Prognosis of grade 3-4 acute GVHD continues to be dismal. Bone Marrow Transplant 2013; 48: 1359-1361.
30. Xhaard A, Rocha V, Bueno B, de Latour RP, Lenglet J, Petropoulou A et al. Steroidrefractory acute GVHD: lack of long-term improved survival using new generation anticytokine treatment. Biol Blood Marrow Transplant. 2012; 18: 406-413.
31. Arai S, Margolis J, Zahurak M, Anders V, Vogelsang GB. Poor outcome in steroidrefractory graft-versus-host disease with antithymocyte globulin treatment. Biol Blood Marrow Transplant 2002; 8: 155-160.
32. Bay JO, Dhedin N, Goerner M, Vannier JP, Marie-Cardine A, Stamatoullas A et al. Inolimomab in steroid-refractory acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: retrospective analysis and comparison with other interleukin-2 receptor antibodies. Transplantation 2005; 80: 782-788.
33. Carpenter PA, Lowder J, Johnston L, Frangoul H, Khoury H, Parker P et al. A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroidrefractory acute graft-versus-host disease. Biol Blood Marrow Transplant 2005; 11: 465-471.
34. Perales MA, Ishill N, Lomazow WA, Weinstock DM, Papadopoulos EB, Dastigir H et al. Long-term follow-up of patients treated with daclizumab for steroidrefractory acute graft-vs-host disease. Bone Marrow Transplant 2007; 40: 481-486.
35. Bordigoni P, Dimicoli S, Clement L, Baumann C, Salmon A, Witz F et al. Daclizumab, an efficient treatment for steroid-refractory acute graft-versus-host disease. Br J Haematol 2006; 135: 382-385.
36. Passweg JR, Orchard K, Buergi A, Gratwohl A, Powles R, Goldman J et al. Autologous/ syngeneic stem cell transplantation to treat refractory GvHD. Bone Marrow Transplant 2004; 34: 995-998.
37. Taniguchi Y, Yoshihara S, Hoshida Y, Inoue T, Fujioka T, Ikegame K et al. Recovery from established graft-vs-host disease achieved by bone marrow transplantation from a third-party allogeneic donor. Exp Hematol 2008; 36: 1216-1225.
38. Ustun C, JillelLa A, Shah R, Sterling K, Deremer D, Savage N et al. Second allo-SCT from a different donor can improve severe steroid-resistant gut GVHD (Letter to the Editor). Bone Marrow Transplant 2010; 45: 1658-1660.
39. Taniguchi Y, Ikegame K, Yoshihara S, Sugiyama H, Kawase I, Ogawa H. Treatment of severe life-threatening graft-versus-host disease by autologous peripheral blood stem cell transplantation using a nonmyeloablative preconditioning regimen. Haematologica 2003; 88: ELT06